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HENLEY, C. M., III, H.-J. GERHARDT AND J. SCHACHT. Inhibition of inner ear ornithine decarboxylase by neomy- 
cin in-vitro. BRAIN RES BULL 19(6) 695-698, 1987.-We quantitated the activity of omithine decarboxylase (ODC) in 
homogenates and subcellular fractions of inner ear tissues from the rat and guinea pig and demonstrate inhibition of 
cochlear ODC by the aminoglycoside neomycin. Subcellular fractionation showed the enzyme associated with the post- 
mitochondrial supematant fraction in each of the tissues: Specific activities of ODC, defined as cr-difluoromethylomithine 
(DFMO)-sensitive decar~xylatio~ of ornithine, in the supematant fractions of combined inner ear tissues were: guinea 
pig=4424 pmoles CO, produce~hour/mg protein, and rat= 133130. In the guinea pig, supernatant fractions of the lateral 
wall tissues (stria vascularis and spiral ligament) had specific activities of 62-e25, those of the organ of Corti (plus VIIIth 
nerve) 64~41. The ototoxic aminoglycoside neomycin produced a dose-dependent inhibition of ODC with half-maximal 
inhibition observed at 50 PM drug and almost complete inhibition at 100 PM. This is the first report of the presence of ODC 
in the inner ear and its inhibition by neomycin. Since both the ODC-inhibitors, DFMO and neomycin, can cause hearing 
loss in patients and experimental animals it is suggested that inhibition of ODC may be an important factor in the ototoxicity 
of these drugs. 
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ORNITHINE decarboxylase (ODC), a ubiquitous enzyme 
regulating the biosynthesis of the polyamines putrescine, 
spermidine and spermine, plays a major role in cellular 
growth, development, maintenance and regeneration [IZ]. 
Interest in this enzyme and the polyamines in the inner ear 
arises from clinical observations that administration of the 
antitumor and antiprotozoal agent a-difluoromethylomithine 
(DFMO), an irreversible inhibitor of ODC, has led to hearing 
loss in patients receiving the drug [l, 2, 171. In addition, a 
number of observations suggest that interactions between 
the ototoxic and nephrotoxic aminogIycosides and 
polyamines may contribute to the toxicity of these drugs. 
For example, we have demonstrated the inhibition of renal 
ODC activity by aminoglycoside antibiotics (Henley et al. in 
preparation) and competition for polyamine transport in the 
inner ear [21]. In addition, the polyamines compete with 
aminoglycosides for renal binding and uptake fS,9]. 
ODC has not been documented in the inner ear. Although 
a recent study detected the polyamines spermidine and 
spermine in the cochlea of rats, neither putrescine nor ODC 
activity was found [ 151. We demonstrate that ODC is present 
in the tissues of the rat and guinea pig cochlea and that the 
enzyme is inhibited in a dose-dependent manner by the 
ototoxic aminogiycoside neomycin. 
METHOD 
Sprague-Dawley rats (18&200 g; Charles River Labora- 
tories, Wilmington, MA) or pigmented guinea pigs (approx- 
imately 250 g; Murphy Breeding Laboratories, Plainsfield, 
IN) were briefly anesthetized with ether. Following cardiac 
perfusion with phosphate-buffered saline (PBS) at room 
temperature to flush the cochlear blood vessels the animals 
were decapitated and the auditory bullae removed. Each 
bulla was then opened to expose the cochlea. At this time the 
cochlea was perfused with an ice cold Ringer’s solution con- 
taining 2 mM dithioerythritol (DTE), 50 PM pyridoxal phos- 
phate (PLP) and 10 PM phenylmethylsulfonyluoride (PMSF; 
a protease inhibitor) from the round window to an exit hole in 
the apex. The cochlear bone was then removed under a dis- 
secting microscope and the inner ear tissues dissected at 4°C 
in PBS containing 10 PM PMSF. 
Tissues from both the right and left ears were combined 
and homogenized in 60 to 140 ~1 of ice cold 50 mM HEPES 
(N-Zhydroxyethyl-1-piperazine-N*-Zethanesulfonic acid), pH 
7.2, 2 mM DTE, 50 PM PLP and 10 ,uM PMSF. The total 
homogenate, ~stmito~hondri~ supematant (13OOOxg for 20 
min at 4°C) and the resuspended pelleted fractions were ana- 
lyzed for ODC activity. ODC was assayed by a modification of 
the procedure by Russell and Snyder [ 131. Aliquots (20 ~1) of 
the fractions were incubated for 60 min at 3PC in (final concen- 
trations) 50 mM HEPES, pH 7.2, 2 mM DTE, 0.1 mM 
ethylenediaminetetraacetic acid (EDTA), 50 FM PLP 
and 100 FM L-omithine (0.25 &i to OS @Zi L-[l-‘4C] 
omithine, 54.3 mCi/mmole; New England Nuclear, 
Boston, MA), at a total volume of 50 or 100 ~1. Incuba- 
tions were terminated by the addition of 200 ~1 4 N HzS04 
and post-incubated for 30 min to trap the evolving ‘4c02 on 
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FIG. I. Omithine decarboxylase activity (pmoles CO, producedihourimg protein) was 
assayed as described in the Method section in the presence of varying concentrations of 
neomycin. Data points represent the percent of specific activity of ODC (meanscstand- 
ard errors) compared to control incubations without drug. ODC activity in the controls 
was 44+5 for n= 12 experiments in each of which duplicate or triplicate incubations 
were performed in parallel to those with neomycin. 
filter disks saturated with 40% KOH. Radioactivity on the 
filters was quantitated by liquid scintillation counting. For 
each experiment, control incubations for nonenzymati~ and 
nonspecific decarboxylation were performed by adding 500 
PM DFMO (nonspecific) to the assays or substituting 20 pg 
bovine serum albumin (BSA; nonenzymatic) for the tissue. 
DFMG insensitive activity (nonspecific decarboxylation) 
was defined as the difference in activity between incubations 
in the presence of DFMO and incubations with BSA. ODC 
activity was defined as the DFMO-sensitive decarboxylation 
of ornithine. 
DFMO was a gift from Merrell Dow Research Institute 
(Cincinnati, OH). Other chemicals were purchased from 
Sigma Chemical Company (St. Louis, MO). 
RESULTS 
ODC Activity in Combined Inner Ear Tissues 
ODC activity was measured in homogenates and subcellu- 
lar fractions of the inner ear tissues of both the rat and guinea 
pig. In homogenates of combined inner ear tissues, mean 
specific activities of ODC were 134 pmoles CO.Jhr/mg 
protein for the rat and 22 for the guinea pig (Table 1, last 
column). In addition, considerable nonspecific decarboxyla- 
tion of ornithine (not related to ODC) was evident: 46+ 16 in 
rat and 5% 1 in the guinea pig (Table 1, + DFMO). 
Subsequent examination of subcellular fractions demon- 
strated that ODC was associated only with the 
postmitochondrial supematant fraction (Table 1): 133230 
pmoles CO, in the rat and 44k4 in the guinea pig and no 
activity in the pellet. Fu~he~ore, nonspecifk decarboxy- 
lation (+ DFMO) was negligible (rat, 2-c2; guinea pig, OrtO) 
in the supematant . In contrast, decarboxylation of omithine 
by the resuspended pelleted fractions was not inhibited by 
500 FM DFMO. 
ODC Activity in Individual Cochlear Tissues 
ODC was subsequently examined in dissected structures 
of the guinea pig inner ear, namely the tissues of the lateral 
wall (stria vascularis & spiral ligament) and the organ of 
Corti (including VIIIth nerve fibers). Total homogenates as 
well as the supematant and pelleted fractions were assayed 
(Table 1). Activity attributable to ODC in tissue homoge- 
nates was 62r5 pmoles CO$hr/mg protein for the lateral wall 
and 341-10 for the organ of Corti (Table 1, Column 3). As 
with the combined inner ear tissues, a considerable 
nonspecific decarboxylation (not sensitive to inhibition by 
DFMO) of omithine was also observed (Table 1, + DFMO). 
For the prep~ation of subcellular fractions from sepa- 
rated tissues six ears were pooled in order to achieve a high 
protein concentration. Specific activity of ODC was 62*25 
for lateral wall and 64541 for organ of Corti (Table 1, Col- 
umn 3). Protein concentrations in assays with six pooled ears 
averaged 2% pg/ml for the lateral wall tissues and 172 *g/ml 
for the organ of Cork Maintenance of a high protein concen- 
tration was essential since loss of ODC activity resulted 
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TABLE 1 
ORNITHINE DECARBOXYLASE IN COCHLEAR TISSUE 
pmoles CO, Produced/hr/mg Protein 
DFMO 
Sensitive 
- DFMO + DFMO Activity 
Rat 
Combined inner ear tissues 
Homogenate (n=4) 180 ? 21 46 ?16 134 ? 24 
Supematant (n=3) 133 * 30 2 22 133 + 30 
Pellet (n=4) 109 * 22 113 + 38 0 
Guinea Pig 
Combined inner ear tissues 
Homogenate (n =6) 27 * 2 5 21 222 1 
Supematant (n=21) 44 + 4 0 *o 442 4 
Pellet (n=3) 18 2 6 19 + 12 0 
Stria vascularis and spiral ligament 
Homogenate (n=4) 93 f 5 31 * 7 62+ 5 
Supernatant (six ears) (n=3) 62 + 25 0 20 62 ? 25 
Pellet (n=4) 0.3 + 0.2 0.4 2 0.4 0 
Organ of Corti plus VIIIth nerve 
Homogenate (n=4) 49 210 15 * 1 34 2 10 
Supernatant (6 ears) (n=3) 64 241 0 *o 64 ? 41 
Pellet (n=4) 32 2 15 15 * 15 lo? 4 
Ornithine decarboxylase activity was assayed as described in the Method section. All values are 
corrected for non-enzymatic decarboxylation (i.e., BSA-blanks are subtracted). ODC is defined as 
“DFMO-Sensitive activity,” i.e., total activity (- DFMO) minus nonspecific activity (+ DFMO). 
Values are means * standard errors from (n) independent experiments in which duplicate or tripli- 
cate assays were performed. 
when tissues from only two pooled ears was assayed. In such 
a case, activity in the stria vascularis and spiral ligament was 
low (544 pmoles COdhrlmg protein) and in the organ of 
Corti it was nondetectable. 
In agreement with the results from the combined ear tis- 
sues, no significant ODC activity was present in the pelleted 
fractions of the individual tissues. 
Neomycin Inhibition of Cochlear ODC 
Inhibition of ODC by neomycin was studied in the 
postmitochondrial supernatant fractions of combined inner 
ear tissues. Final concentrations of neomycin varied from 1 
PM to 1 mM and duplicate or triplicate incubations were 
performed in parallel with control incubations with and 
without DFMO. Neomycin produced a dose-dependent in- 
hibition of cochlear ODC. Activity was reduced to 54*5% in 
the presence of 50 PM neomycin and almost completely 
inhibited by 100 PM neomycin. 
DISCUSSION 
The study clearly demonstrates the presence of ODC ac- 
tivity in the tissues of the inner ear of both the rat and the 
guinea pig. The reason why the specific activity is signifi- 
cantly higher in the rat remains speculative. Higher ODC 
activities are generally found during development but the 
animals used here should be considered mature. Neverthe- 
less, age may have been a factor since preliminary studies in 
the young (10 and 11 days) hooded rat showed up to ten-fold 
higher cochlear ODC activity (Henley et al., unpublished) 
and the postnatal developmental pattern of ODC and 
polyamines in cochlear tissues has not been characterized. 
Guinea pigs were chosen for the detailed studies of ODC 
since the species is ideally suited for surgical access to the 
cochlea and subsequent dissection of its tissues [4]. More 
importantly, the guinea pig yields greater amounts of tissue 
from the inner ear. For example, while combined tissues 
from one rat cochlea provided 12 to 33 pg protein, yield from 
the guinea pig was two- to three-fold greater providing 58 to 
80 pg. This is an important consideration since ODC is ex- 
tremely labile in the presence of low protein concentrations 
[lo, 12, 161 and sensitive to dilution during all stages of 
purification procedures [7]. In fact, ODC activity was more 
consistently detected in the guinea pig than in the rat. In 
addition to the experiments reported in Table 1, four incuba- 
tions with rat tissues (out of a total of 15) did not show 
activity, whereas in the guinea pig only two incubations (out 
of a total of 46) failed to detect ODC. The necessity for 
maintaining higher protein concentrations became evident 
again when supernatant fractions of individual tissues were 
assayed. These results confirm the requirement for adequate 
protein concentrations to stabilize the enzyme. This insta- 
bility of ODC may have contributed to the inability of 
Schweitzer et al. [ 151 to detect this enzyme in the inner ear. 
The clinical use of DFMO in cancer chemotherapy and 
aminoglycosides in the treatment of bacterial infections has 
698 HENLEY, GERHARDT AND SCHACHT 
resulted in loss of hearing. The demonstration of DFMO- 
sensitive ODC in cochlear tissues and its inhibition by 
neomycin agrees well with our previous findings of amino- 
glycosideipolyamine antagonism {21]. It suggests that ODC 
and polyamine-regulated cellular functions may be targets of 
these drugs. While the mechanism of DFMO ototoxicity is 
unknown, a tenable hypothesis has been offered for amino- 
glycoside ototoxicity [ 141 including a possible action on ODC. 
The enzyme may not necessarily be the primary site of drug 
action but it is suggested that drug effects on polyamine syn- 
thesis and function potentiate the injury induced by amino- 
glycosides. It is well established that drug-induced or other 
noxious insults to a target cell may result in induction of 
ODC and polyamine synthesis as part of a compensatory 
repair mechanism 13, 6, 7, 221. Thus, inhibition of a recovery 
response by the aminoglycoside itself could contribute to cell 
death. 
A similar argument can be made for the known potentia- 
tion of noise-induced cochlear damage by aminoglycosides. 
Noise-induced cellular damage may be followed by induction 
of ODC in tissue recovery. Aminoglycoside inhibition of 
ODC would block this repair process. Another example for a 
possibly critical role of ODC as a drug target is the develop- 
ing animal. Polyamines are crucial effecters of cellular de- 
velopment and postnatal inhibition of ODC by DFMO has 
been shown to produce marked retardation of brain growth 
[18-201 and development of complex integrative behaviors 
IS]. The increased susceptibility to aminoglycoside-induced 
ototoxicity in the embryonic and young animal [ I I] may be a 
consequence of ODC inhibition. 
While the role of ODC in drug-induced ototoxicity re- 
mains speculative the proposed mechanisms are testable and 
interesting in view of the crucial involvement of ODC in 
cellular regulation. The fact that two distinctly different 
ototoxic drugs inhibit this enzymatic activity is highly in- 
triguing. 
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